bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
3.290
-0.210 (-6.00%)
At close: May 12, 2025, 4:00 PM
3.420
+0.130 (3.95%)
After-hours: May 12, 2025, 7:26 PM EDT
bluebird bio Revenue
In the year 2024, bluebird bio had annual revenue of $83.81M with 184.12% growth. bluebird bio had revenue of $38.52M in the quarter ending December 31, 2024, with 391.72% growth.
Revenue (ttm)
$83.81M
Revenue Growth
+184.12%
P/S Ratio
0.38
Revenue / Employee
$337,931
Employees
248
Market Cap
32.21M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BLUE News
- 3 days ago - Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital - Business Wire
- 7 days ago - Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio - Business Wire
- 26 days ago - bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - Business Wire
- 6 weeks ago - Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps - Benzinga
- 6 weeks ago - Bluebird bio receives non-binding bid for up to $110.5 million - Reuters
- 6 weeks ago - Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update - Market Watch
- 6 weeks ago - bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Business Wire
- 2 months ago - BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE - Business Wire